ERBB2 and non-small cell lung carcinoma: DESTINY-Lung02 [81] was a blinded, multicenter, phase II trial of trastuzumab deruxetequan (5.4 mg and 6.4 mg per kg body weight) in patients with treatment-naive NSCLC with metastatic HER2 mutations.